The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

A phase III study has demonstrated that 6-month pasireotide treatment induced disease control with good safety in 15–26% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the 6-month efficacy and safety of pasireotide treatment according to the real-world evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivonello, Rosario, Arnaldi, Giorgio, Scaroni, Carla, Giordano, Carla, Cannavò, Salvo, Iacuaniello, Davide, Trementino, Laura, Zilio, Marialuisa, Guarnotta, Valentina, Albani, Adriana, Cozzolino, Alessia, Michetti, Grazia, Boscaro, Marco, Colao, Annamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551343/
https://www.ncbi.nlm.nih.gov/pubmed/30968338
http://dx.doi.org/10.1007/s12020-018-1818-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551343/
https://www.ncbi.nlm.nih.gov/pubmed/30968338
http://dx.doi.org/10.1007/s12020-018-1818-7

Ejemplares similares